Head and Neck Cancers Pipeline Therapies
According to GloboCan, “the HNSCC incidence in the US in 2020 was estimated to be 63,520 cases. As per estimates, it was observed that HNSCC is slightly more common in men than in women”
Some of the major HNSCC treatment options available in the market include surgery, radiation therapy, chemotherapy, and targeted therapy. As per the DelveInsight, the expected approval and entry of the pipeline therapies for HNSCC treatment is expected to fuel the market growth during the forecast period 2021–2030. Along with these, the improvement in the diagnosis methodologies and the incremental healthcare spending across the world would also improve the market dynamics.
At present some of the key companies such as Merck, Sinocel tech, GSK, Roche, AstraZeneca, Aveo Pharmaceuticals Private Limited, and others are actively working in the Head and Neck Cancers treatment market landscape.
For more details, visit: Head and Neck Cancers Pipeline Therapies